INTEST CORP
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $INTT in the last 30 days.
See all $INTT insider activity →inTest (INTT) shares fell 10.2% premarket to $13.50 after a Q3 2026 update. The company expects orders of $48M-$50M, up 28%-33% YoY, and revenue at the high end of its $33M-$35M guidance. Gross margin details were not provided. Full results are due November 6, 2026.
inTest Corporation's stock dropped 10.2% to $13.50 in pre-open trading after a preliminary Q3 2026 update. The company reported expected Q3 orders of $48M-$50M, a 28%-33% YoY growth, but investors sold due to high expectations and technical overextension. Gross margin concerns persist, with Q2 2026 margins 500 basis points below guidance. The broader market is up slightly.
Vaxcyte shares surged 54% after positive Phase 3 vaccine trial results. PTC shares rose 34% following a $22.6B takeover by Schneider Electric. RXO shares jumped 24% after a $5.8B acquisition deal by C.H. Robinson. InTest shares climbed 24% on record Q3 orders, signaling strong semiconductor demand.
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning INTT (INTEST CORP). Coverage has skewed bullish: 5 bullish, 0 neutral, and 2 bearish.
Recent INTT coverage spans earnings, market movers and financial news.
The preliminary guidance, while record‑high, triggered profit‑taking and margin concerns, pressuring the stock.
The preliminary update failed to exceed expectations, prompting profit‑taking and pressure on the stock.
Strong order flow suggests continued demand for semiconductor test equipment.
Guidance at the high end signals stronger demand and may lift the stock.
Guidance beat expectations, likely driving share price higher.
AlphAI scores every news story that mentions INTT with an AI model for sentiment and relevance, and aggregates insider trades from INTEST CORP's SEC EDGAR Form 4 filings. Figures refresh continuously.
inTest (INTT) shares fell 10.2% premarket to $13.50 after a Q3 2026 update. The company expects orders of $48M-$50M, up 28%-33% YoY, and revenue at the high end of its $33M-$35M guidance. Gross margin details were not provided. Full results are due November 6, 2026.
2 min readinTest Corporation's stock dropped 10.2% to $13.50 in pre-open trading after a preliminary Q3 2026 update. The company reported expected Q3 orders of $48M-$50M, a 28%-33% YoY growth, but investors sold due to high expectations and technical overextension. Gross margin concerns persist, with Q2 2026 margins 500 basis points below guidance. The broader market is up slightly.
1 min readVaxcyte shares surged 54% after positive Phase 3 vaccine trial results. PTC shares rose 34% following a $22.6B takeover by Schneider Electric. RXO shares jumped 24% after a $5.8B acquisition deal by C.H. Robinson. InTest shares climbed 24% on record Q3 orders, signaling strong semiconductor demand.
2 min readINTEST CORP (INTT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE 804 EAST GATE DRIVE, SUITE 200, MOUNT LAUREL, NJ 08054 FOR IMMEDIATE RELEASE InTest Expects Record Orders for Q3 2026 and Revenue at High End of Guidance Range for Q3 and Full Year 2026 • Q3 orders 1 expected to be $48 million to $50 million, driven by r
2 min readInTest Corporation (INTT) anticipates record Q3 2026 orders and revenue at the high end of its guidance, driven by strong semiconductor demand. The company also expects full-year revenue to meet the upper range of its forecast.
1 min readINTEST CORP (INTT) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement The information set forth in Item 2.03 of this Current Report on Form 8-K (this “Current Report”) is incorporated herein by reference. Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance
4 min readInTest reported a third consecutive profitable quarter. Gross margin was 40.5%, down sequentially and YoY, which management attributed to product mix. Operating expenses fell QoQ due to the prior quarter’s restructuring charge, but rose YoY on payroll. Net income was $0.5m ($0.04/share), adjusted $1.1m ($0.09). Cash rose to $22.1m.
2 min readInTest (INTT) reported Q2 2026 revenue of $35.3M, up 25.5% YoY, with semi orders $12.0M (+64% YoY) and backlog $45.4M (+19.8% YoY). Full-year guidance raised to $135M-$140M. Gross margin was 40.5% and adjusted EBITDA $2.2M. CFO cited a material weakness at Alfamation.
6 min readINTEST CORP (INTT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NEWS RELEASE 804 EAST GATE DRIVE, SUITE 200, MOUNT LAUREL, NJ 08054 FOR IMMEDIATE RELEASE InTest Reports Strong Second Quarter 2026 Revenue of $35.3 Million EPS of $0.04 and Adjusted EPS (Non-GAAP) of $0.09 • Second quarter revenue up 25.5% year-over-year, driven lar
6 min readinTest Corp (INTT) shares rose 1.7% in pre-open trading after Northland upgraded the stock to “outperform” from “market perform” and set a $15.00 price target. Northland cited inTest’s preliminary Q2 2026 revenue estimate of about $35M and raised full-year 2026 revenue guidance to $135M-$140M, while noting a planned 220 bps gross margin reduction.
3 min read
